Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study
- 11 September 2003
- Vol. 327 (7415) , 603
- https://doi.org/10.1136/bmj.327.7415.603
Abstract
Helicobacter pylori is an important risk factor for peptic ulcers. If infection with H pylori is cured, ulcers associated with H pylori do not recur. An H pylori “test and treat” strategy for patients with peptic ulcers having long term antisecretory treatment has been suggested, in the hope that eradicating H pylori would curtail the rising use of antiulcer drugs.1 2 We describe the long term effect of eradicating H pylori on the use of antiulcer medication in a population of patients with peptic ulcers. We included all patients in the Danish county of Funen (population 470 000) who redeemed their first prescription for eradicating H pylori between 1 January 1992 and 31 December 1996 and who had uncomplicated peptic ulcers endoscopically verified before or at the date of redeeming this prescription. We drew data on gastroscopically and endoscopically verified diagnoses of peptic ulcers …Keywords
This publication has 5 references indexed in Scilit:
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002
- Search and treat strategy to eliminate Helicobacter pylori associated ulcer diseaseGut, 2001
- When an Entire Country Is a CohortScience, 2000
- Symptomatic benefit 1-3 years after h. pylori eradication in ulcer patients: impact of gastroesophageal reflux diseaseAmerican Journal of Gastroenterology, 2000
- The Danish prescription registries.1997